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The interaction has been studied of several anthraquinone-based intercalating drugs, including the anti-can- 
cer agent mitoxantrone, with defined sites of DNA. A 160 base pair DNA sequence from tyrT was employed 
for footprinting with DNase I. The anthraquinones had aminoalkylamino substituents in various positions 
of the ring system. Inhibition of enzymatic cutting of the DNA was observed at various positions on the 
sequence, mostly around some of the pyrimidine-3’,5’-purine sites. Enhancements to cutting were observed 
clustered around AT-rich regions. The compounds showed differences in detailed footprinting behaviour, 
which have been related to differences in their mode of interaction with DNA as found in earlier computer 
modelling studies. 
Anthraquinone Mitoxanthrone Intercalator Footprinting 
1. INTRODUCTION 
The aminoalkylamino-disubstituted anthra- 
quinone compound I, mitoxanthrone (fig.l), has 
established experimental anti-tumour activity [1,2] 
and is now coming into clinical use for the treat- 
ment of human cancers [3,4]. A number of studies 
have shown that it binds to DNA in vitro, and that 
intercalative processes are involved [5-91. Thus, 
mitoxanthrone unwinds closed circular duplex 
DNA by 14-17“ per bound drug molecule, 
displaces bound ethidium from its DNA complex, 
and itself produces spectroscopic changes on 
binding characteristic of an intercalator. The drug 
is an inhibitor of nucleic acid synthesis [lo] and 
causes DNA strand breaks in vivo [I 11. It is 
generally presumed that these effects are causally 
related to its anti-tumour activity. 
A recent study has been made on a series of 
* To whom correspondence should be addressed 
substituted anthraquinones (II-V, fig.1) that dif- 
fer in the pattern of substitution, using a combina- 
tion of solution methods for investigating DNA 
% R, 
0 o”o 0 
Rs R, 
I R, = R~ = NH(cH~)~ ~H(cH~)~~H, R~ = R~ = OH 
II R, = NHKH+$H(C2H5+, R4 = R5 = R8 = H 
+ 
III R, = R4 = NH(CH2)2NH(C2H5)2, R5 = R8 = H 
+ 
IV R, = R5 = NH(CH,)2NH(C2H5)2, R4 = R8 = H 
+ 
V R, = R8 = NHKH2)2NHlC2H5)2, R4 = R5 = Ii 
Fig. 1. Structural formulae of anthraquinones used in 
this study. 
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binding, and computerised molecular modelling 
[ 121. The 1 ,Cdisubstituted compound is analogous 
to mitoxanthrone itself, with the side chain in this 
series differing only slightly from that of the 
established rug. All four compounds were shown 
to bind intercalatively to DNA. There were signifi- 
cant differences in the strength of binding amongst 
the members of the series, which correlated with 
the ranking order of calculated interaction 
energies. The modelling also suggested that there 
are differences in the orientation and positioning 
of these anthraquinones when bound in their 
respective DNA intercalation sites. 
This investigation extends these studies to ques- 
tions of DNA site selectivity, preference and 
dynamics. Footprinting, which involves examining 
drug-induced inhibition of cleavage of defined- 
sequence DNA fragments by either enzymatic [13] 
or chemical [ 141 agents has been shown to be an ef- 
fective technique for addressing these questions. 
Structurally ‘complex’ intercalators such as ac- 
tinomycin [ 15,161, the quinoxaline antibiotics 
[ 13,141, and the anthracycline nogalamycin [171 all 
induce large changes in the cleavage pattern, con- 
sistent with the existence of definite nucleotide se- 
quence preferences. ‘Simple’ intercalators do not 
generally produce clear footprinting patterns, 
presumably because they lack selectivity. The 
technique is also dependent on the relative per- 
sistence of drugs at different sites on DNA, and 
simple intercalators generally dissociate rapidly 
from DNA rendering their positions more difficult 
to detect by standard footprinting methods. 
2. EXPERIMENTAL 
Mitoxanthrone (I) and the anthraquinones II-V 
were synthesised according to published pro- 
cedures. Nogalamycin was a gift from Dr P.F. 
Wiley of the Upjohn Co., Kalamazoo, MI. Stock 
solutions of each antibiotic were prepared by direct 
weighing and dissolved in 10 mM Tris-HCl (pH 
7.5) containing 10 mM NaCl. DNase I was ob- 
tained from Sigma and prepared as a 7200 U/ml 
stock solution in 0.15 M NaCl containing 1 mM 
MgC12. This was stored at -20°C and diluted to 
working concentrations immediately before use. 
2.1. DNA substrates 
The 160 base-pair tyrT fragment was isolated 
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and labelled as described [ 13,18,19]. Incubation 
with reverse transcriptase, dCTP and [m-32P]dCTP 
led to selective labelling of the 3 ‘-end of the top 
strand (fig.3) whereas incubation with dTTP and 
[cu-32P]dATP led to selective labelling at the 3 ’ -end 
of the bottom strand. Bands in the tyrT digestion 
pattern were assigned by running dimethylsul- 
phate-piperidine markers specific for guanine, as 
previously described. 
2.2. DNase I footprinting 
Digestion with DNase I was performed as 
previously described. Samples of the labelled DNA 
fragment (3 pmol in base-pairs per gel lane) were 
incubated with antibiotic solution at 37°C for 
30 min (sufficient to ensure an equilibrium of the 
ligand), then cooled to 4°C and digested with 
DNase I dissolved in 20 mM NaCl, 2 mM MgClz, 
2 mM MnClz at a final enzyme concentration of 
0.01 U/ml. Experiments were performed at this 
low temperature to increase the persistence time of 
the ligands on the DNA and sharpen the protection 
pattern (Fox, unpublished). Aliquots (3 ~1) were 
removed from the mixture after various times and 
the reaction was stopped by adding 2.5 1 of 80% 
bromophenol blue, 10 mM EDTA and 1 mM 
NaOH. Samples were heated at 100°C for at least 
3 min prior to electrophoresis. 
2.3. Gel electrophoresis 
The products of tyrT digestion were analysed on 
0.3 mm 8% (w/v) polyacrylamide gels containing 
8 M urea and Tris-borate-EDTA buffer (pH 8.3). 
After 2 h electrophoresis at 1500 V the gel was 
soaked in 10% acetic acid for 10 min, transferred 
to Whatman 3MM paper, dried under vacuum at 
80°C and subjected to autoradiography at - 70°C 
with an intensifying screen. 
3. RESULTS 
Fig.2 shows an autoradiograph of DNase I 
digestion patterns for the tyrT fragment labelled 
on the lower strand in the presence and absence of 
mitoxanthrone (I), the four synthetic anthra- 
quinones (II-V) and nogalamycin. 
The changes in the cleavage pattern induced by 
nogalamycin (extreme right lanes) reveal a number 
of positions that are protected from cleavage by 
the enzyme. These are centred around positions 21, 




Fig.2. DNase I digestion patterns for the tyrT DNA, 
labelled at the 3 ‘-end of the lower strand, in the presence 
of mitoxanthrone and related anthraquinones (final 
concentration 20 M), and nogalamycin (1 M). Each pair 
of lanes represents digestion by the enzyme for 2 and 
10 min. Track G is a dimethylsulphate-piperidine 
marker specific for guanine. 
37, 41, 60, 92 and 117 and are in accord with a re- 
cent study on this drug. As previously noted a 
number of bands appear strongly enhanced in the 
presence of this antibiotic, due to increased sen- 
sitivity to the enzyme. Enhanced cleavage is most 
noticeable at positions 81, 86, 110 and 127 (fig.2). 
The five anthraquinones all provoke changes in 
the DNase I cleavage pattern. These changes are 
different for the various ligands and are generally 
less pronounced than those produced by 
nogalamycin, even at IO-fold higher concentra- 
tion. The bands which show a decreased rate of 
cleavage are summarised in table 1. 
Various regions where DNase I cleavage is 
enhanced have also been identified (table 2). These 
enhancements are not identical for each of the dif- 
ferent anthraquinones and are distinct even on 
visual inspection. For example, the intense 
enhancement produced by nogalamycin around 
position 81 (visible on the lower strand) is paral- 
leled only very weakly by the 1,8_anthraquinone, 
although this anthraquinone is the only one to pro- 
Table 1 
Major positions of protection against DNase I cutting 
for the tyrT DNA fragment 
I-AQ l,4-AQ l,S-AQ 1,8-AQ Mito- Nogala- 
xanthrone mycin 
21-23 21-23 21-23 21-23 
(weak) 
37-38 37-41 37-38 37-38 37-38 
(weak) 
41 
55 57-61 55-57 
(weak) 
59-60 59-61 59-61 59-61 
86-87 86-87 86-87 69 




The first four columns refer to the aminoethyl 
(aminodiethyl)-substituted anthraquinones as indicated 
Table 2 
Major sites of enhancement towards DNase I cutting on 
the tyrT DNA fragment 
I-AQ 1,4-AQ 1,5-AQ 1,8-AQ Mito- Nogala- 
xanthrone mycin 
28-30 28-30 28-30 28-30 28-30 28-30 
39 48-51 
53-55 50 
84-85 84-85 84 85 85 
(weak) 
107 94 91 86 
121 
127 125 127 127 
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5’-AATTCCGGTTACCTTTAATCCGTTACGGATGAAAATTACGCAACCAGTTCATTTT TCTCAACGTAACACTTTACAGCGGCGCGT 
0 . . . . 50 . ,D . IO * 80 
~‘-TTAAGGCCAATGG~OAATTAGGCA~GCC;ACTT~AATGCGTT~~TCAAGTAAAAAGAGTTGCATTGTGAAATGTC~CGCGCA 
CATTTGATATGATG~G~C~CGCT~~CCGATAAGGGAG~AGGCCAGTAAAAAG~ATTA~~~~GTGGTGGGGGTTCCCG - 3’ 
80 . . . . 110 . 
=TAAACTATA~~TACGCGGG~~GAAG~GCT~~TCCETCGT~~GGTCATTT~~CGTA*ATGG~~CACCACCCCCAAGGGCT-~’ 
Fig.3. Sequence and numbering scheme for the tyrT DNA fragment. 
duce a marked enhancement of cutting around 
position 91. 
Fig.3 shows the sequence of the tyrT fragment 
used. There is no general correlation between the 
two types of site enhancement or reduced cleavage; 
some protected sites are clustered together with 
enhanced ones, whereas a number of sites showing 
enhanced cleavage appear remote from protected 
ones. The protected sites are mostly at, or close to 
the sequences CG, CA and TA (reading in the 
5 ’ -3 ’ direction). As previously noted the majority 
of the enhanced regions lie in, or close to, short 
non-alternating AT runs. 
4. DISCUSSION 
It is now well established that certain structural- 
ly complex intercalators such as echinomycin, ac- 
tinomycin or nogalamycin interact non-randomly 
in a sequence-specific manner with DNA. For all 
of these drugs, as well as for the AT-specific 
groove binders netropsin [ 181 and distamycin [ 151, 
plausible molecular mechanisms have been ad- 
vanced to explain their sequence-specificity that 
take account of their structural complexity. It is 
then at first sight surprising that in this study even 
the simplest anthraquinones have been shown to 
exhibit some ability (albeit limited) to discriminate 
between various sequences, not only as regards 
protection from nuclease attack but also in pro- 
ducing non-random enhancement of the enzyme 
cutting rate. The sites inhibited by the drugs are 
mostly of the pyrimidine-3 ’ ,5 ’ -purine type. This is 
in accord with a number of theoretical predictions 
which have indicated that such sites require less 
energy to open up from 3.4 to 6.8 A compared 
with the other possible dinucleotide combinations 
[20-221. NMR studies on simple intercalators [23], 
as well as mitoxanthrone itself bound to short- 
length oligonucleotides [9], have led to the same 
conclusion. 
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It is not surprising that the least changes in the 
cleavage pattern are induced by the simplest an- 
thraquinone, substituted with a single side chain. 
The other three compounds, possessing two iden- 
tical side chains at different positions of substitu- 
tions, produce varying patterns of cutting. We 
have previously shown by computerised molecular 
modelling that these three anthraquinones (the 1,4; 
1,5; 18 derivatives) take up distinct geometrical 
positions as regards intercalation, associated with 
characteristic stabilisation energies. The ranking 
order of energy correlates with the measured 
kinetics of dissociation from DNA [24], and is (in 
order of decreasing stability for an intercalated 
complex) 1,5; 1,4; 1.8; 1. Since the ability of any 
ligand to induce a footprinting pattern depends on 
the strength of interaction and the slowness of 
drug-DNA dissociation, the number of altered 
regions and the level of protection afforded would 
be expected to follow the same order. Inspection of 
table 1 shows that this is indeed the case. We note 
that the number of sites displaying enhanced 
cleavage also follows this same ranking order. 
Of the six DNA-binding compounds examined 
here, four may be grouped into two pairs. Firstly, 
the 1,4-anthraquinone clearly bears a strong struc- 
tural resemblance to the anti-cancer drug mitoxan- 
throne. Both have alkylamino side chains, each 
bearing a single protonated nitrogen atom 
separated from its point of attachment to the 
chromophore by a two-carbon link, although they 
differ slightly in the terminal atoms of the side 
chain. Their behaviour in the footprinting ex- 
periments parallels this structural similarity with 
relatively little difference between them in terms of 
protected sites. The slightly greater number of sites 
protected by mitoxanthrone may be due to involve- 
ment of its side-chain hydroxyl groups in secon- 
dary interactions imparting extra stabilisation at 
certain binding sites. Secondly, molecular model- 
ling studies on the 1,5_anthraquinone [12] and 
Volume 202, number 2 FEBS 
nogalamycin [25] have indicated that they share a 
common non-classical mode of intercalation, with 
their chromophores ‘spearing’ base-pairs at the in- 
tercalation site and their sterically bulky sub- 
stituents (aminoalkyl side chains and sugar groups, 
respectively), situated in both major and minor 
grooves of the DNA. Thus, for these compounds 
intercalation has to be preceded by binding to a 
transiently opened-up site on DNA. Many features 
of this model have been confirmed by kinetic 
[26,27] and footprinting studies on nogalamycin 
[ 171. The comparative footprinting studies 
reported here suggest a marked correspondence 
between these two drugs as regards their preferred 
binding sites, together with differences from the 
others in the series, the most notable occurring at 
site 41 (which is only protected by these two 
compounds). 
It is remarkable that all of the protected and 
enhanced regions for the DNA-binding ligands ex- 
amined in this study cluster around similar 
stretches of sequence. By no means all of the 
pyrimidine-3 ’ ,5 ’ -purine sites are protected from 
cutting by bound drug: those in the GC-rich 
stretches 71-79 and 93-102 are especially promi- 
nent in this regard. These stretches of sequence are 
not major sites of enhancement towards DNase I 
cutting either. Regions of enhancement lie mostly 
(though not exclusively) in the AT-rich sections 
such as 28-30 and around 127. It is known that 
DNase I cleavage is especially sensitive to perturba- 
tions in the double-helical geometry of DNA [ 191, 
and thus the enzyme can sense both local and long- 
range changes induced by the drugs. It is of interest 
that in the absence of drug the enzyme cuts least 
well at long AT and GC runs, presumably because 
in these regions the enzyme cannot readily accom- 
modate the DNA groove widths pertaining there. 
This question of groove widths is also of impor- 
tance in determining differential accessibility as 
regards drug binding. Molecular modelling has in- 
dicated that the drugs examined here do not 
necessarily bind via the same DNA groove. For ex- 
ample, the l-substituted anthraquinone can adopt 
a number of equi-energetic bound states with the 
side chain projecting into either major or minor 
grooves. By contrast, the l,%anthraquinone re- 
quires a wide groove for its side chains, which are 
too large to reside in the minor groove. Sequence- 
dependent variations in groove dimensions would 
LETTERS July 1986 
thus be expected to exert significant influence on 
the binding of this drug. No such effect is actually 
observed since the l,H-anthraquinone affords the 
least protection in the series, but this way may not 
be too surprising since DNase I cuts from the op- 
posing minor groove. The enhancements of cutting 
produced by this drug are perhaps the most 
marked in the series, suggesting that the location 
of its side chain in the major groove induces some 
long-range perturbations. 
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